Crispr Therapeutics Ag (CRSP)
$199.88 10.16 (4.84%)
19:59 EST CRSP Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 9.36B
PE Ratio -
Volume (Avg. Vol.) 4.00M
Day's Range 199.01 - 220.20
52-Week Range 32.30 - 220.20
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.
CRSP stock is rallying today as CRISPR Therapeutics and its gene-editing peers move into the spotlight. Here's what you should know.
It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock.
This Swiss biotechnology company works on the cutting edge of gene editing and Crispr stock is a play on future treatments.
By Alex Sirois
Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.
Crispr Therapeutics (CRSP) news for Wednesday includes a patient's death during a recent drug trial dropping CRSP stock down.
CRSP stock has pulled back 13% in the last two sessions — on no news. The dip allows investors into a strong long-term story at a lower price.
We're still very early in the development of gene editing, and CRISPR Therapeutics is one of the first out of the block. But it's not hte final word.
By Alex Sirois
Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
From Market News Video
Investors in CRISPR Therapeutics AG (CRSP) saw new options become available this week, for the March 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new March 19th contracts and identified one put and one call contract of particular interest.
Navellier RatingsPowered by Portfolio Grader